EDAN(SZ:300206) 仪器信息网·2025-10-29 03:58Financial Performance - The company reported a revenue of 532.27 million yuan for the current period, representing a 15.72% increase compared to the same period last year [2] - Net profit attributable to shareholders increased by 118.28% to 102.17 million yuan, while the net profit excluding non-recurring items rose by 118.08% to 96.16 million yuan [2] - Basic and diluted earnings per share both reached 0.1763 yuan, marking a 118.15% increase [2] Non-Recurring Items - The company recorded a total of 6.02 million yuan in non-recurring gains for the current period, with government subsidies contributing 4.32 million yuan [3] - The total non-recurring gains for the year-to-date period amounted to 15.64 million yuan [3] Balance Sheet Changes - Accounts receivable increased by 61.22% to 235.31 million yuan, primarily due to increased sales to major customers [7] - Other current assets decreased by 70.72% to 1.46 million yuan, mainly due to the refund of prepaid income tax from the previous period [8] - Construction in progress rose by 35.70% to 162.84 million yuan, reflecting increased investment in the company's new facility [8] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 22,710, with the top three shareholders holding significant stakes: Zhang Hao (21.05%), Zu Youdong (17.27%), and Xie Xicheng (17.18%) [21] Strategic Developments - The company is advancing its local manufacturing project in the U.S., having established a new facility in San Diego, which has received necessary certifications [24] - A collaboration with Global Health Labs, Inc. aims to develop an affordable handheld ultrasound device for low-income countries, with funding of 2.796 million USD allocated for the project [25][26] - The project has been further supported by a grant agreement with the Gates Foundation, providing an additional 2.65 million USD for clinical testing and market introduction [26]